🎯 check SNDX-5613 (Revumenib) product page
SNDX-5613 is a menin inhibitor. It affects MLL/NPM1 signaling by enhancing CLL-1 expression, promoting CAR T cell immunity.
SNDX-5613 (Revumenib) MOA:Targeting Menin/HOX Pathway for Acute Leukemia
🎯 check SNDX-5613 (Revumenib) product page
SNDX-5613 is a menin inhibitor. It affects MLL/NPM1 signaling by enhancing CLL-1 expression, promoting CAR T cell immunity.